GlassScriptPhysician profile
Dawn A Broderick
NPI 1801899489
$3,854.23
in general payments reported to CMS, 2019-2025
28 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $627 · 2021: $956 · 2022: $263 · 2023: $508 · 2024: $575 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $739.82 | 2019-2025 | Ubrelvy, Synthroid, Qulipta |
| Pfizer INC. | $475.85 | 2019-2025 | |
| Novo Nordisk INC | $389.94 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $351.86 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $297.92 | 2019-2025 | Breztri |
| Merck Sharp & Dohme LLC | $262.21 | 2019-2024 | Dificid, Verquvo, Pifeltro |
| Exact Sciences Corporation | $229.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $204.58 | 2019-2021 | |
| Allergan, INC. | $173.20 | 2019-2020 | |
| Astellas Pharma US INC | $88.71 | 2019-2021 | |
| Therapeuticsmd, INC. | $62.97 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $59.56 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.01 | 2021-2024 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $44.38 | 2023-2024 | Quviviq |
| Eisai INC. | $42.10 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $40.23 | 2019 | |
| Horizon Therapeutics Plc | $37.06 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $36.54 | 2019 | |
| Janssen Pharmaceuticals, INC | $35.57 | 2024 | Spravato |
| Biohaven Pharmaceuticals, INC. | $33.86 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.46 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $29.34 | 2025 | Zoryve |
| Radius Health, INC. | $28.88 | 2023 | Tymlos |
| Amarin Pharma, INC. | $26.72 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $26.05 | 2025 | Unithroid |
| Genentech USA, INC. | $20.70 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.52 | 2023 | Trintellix |
| Glaxosmithkline, LLC. | $18.79 | 2024 | Arexvy, Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Broderick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.